← Eichor
Study identifier: NCT06754852 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study Assessing HMB-002 in Participants With Von Willebrand Disease

Condition: Von Willebrand Disease (VWD) · Von Willebrand Disease (VWD), Type 1 · Von Willebrand Disease (VWD), Type 2  ·  Sponsor: Hemab ApS

PhasePhase 1/Phase 2
Planned participants108
Who can joinAll sexes, 16 Years to 69 Years
Healthy volunteersNo

About this study

This is a first-in-human (FIH), Phase 1/2, 3-part open-label, dose escalation, safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and efficacy study evaluating HMB-002 in participants with VWD. Part A of the study involves a single ascending dose (SAD) regimen design to establish safety, tolerability, PK, and PD effect. In Part B of the study, the safety and tolerability of repeat dosing will be established prior to cohort expansion to explore efficacy. Part C will evaluate the safety, PK, and PD of a single concomitant dose of HMB-002 and factor concentrate with Type 3 VWD or Type 1 VWD with low residual VWF and FVIII who use factor concentrate as prophylaxis.

This description comes directly from the study's public registry record.

Talk to the study team

Clinical Trials  ·  080 8304 6409  ·  clinicaltrials@hemab.com

Always discuss trial participation with your own doctor first.

Locations (25)

Phoenix Children's HospitalPhoenix, Arizona, United StatesNot Yet Recruiting
Arkansas Children's HospitalLittle Rock, Arkansas, United StatesNot Yet Recruiting
Children's Hospital of Los AngelesLos Angeles, California, United StatesNot Yet Recruiting
University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer CenterMiami, Florida, United StatesNot Yet Recruiting
Emory Children's CenterAtlanta, Georgia, United StatesNot Yet Recruiting
Innovative Hematology, Inc./Indiana Hemophilia and Thrombosis CenterIndianapolis, Indiana, United StatesRecruiting
Tulane University School of MedicineNew Orleans, Louisiana, United StatesNot Yet Recruiting
University of Michigan Hospitals, Department of Hemophilia and Coagulation DisordersAnn Arbor, Michigan, United StatesNot Yet Recruiting
Mayo Clinic - RochesterRochester, Minnesota, United StatesNot Yet Recruiting
Oregon Health & Science UniversityPortland, Oregon, United StatesNot Yet Recruiting
Hemophilia Center of Western PennsylvaniaPittsburgh, Pennsylvania, United StatesNot Yet Recruiting
The University of Texas Southwestern Medical CenterDallas, Texas, United StatesNot Yet Recruiting

+ 13 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06754852